Strong clinical associations between IGF-1R signaling and breast cancer risk and clinical outcomes, as well as extensive preclinical evidence implicating this pathway in multiple aspects of cancer progression, suggest a high therapeutic potential of targeting the IGF pathway in breast cancer. Here, IGF1 is linked to breast carcinoma.